Factores pronósticos en el cáncer de mama en estadio inicial

Almagro, Elena; Gonzalez, C.; Espinosa, Enrique

doi:10.1016/j.medcli.2014.12.019

Cited by 4 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…El Índice pronóstico de Nottingham, descrito por primera vez en 1982, permite utilizar una puntuación clínico-patológica, la cual emplea: 1) el tamaño tumoral, 2) la afectación ganglionar y 3) el grado histológico, dando como resultado a 3 grupos pronósticos: 1) Grupo de buen pronóstico (supervivencia del 80 %), 2) Grupo de moderado pronóstico (supervivencia del 42 %) y 3) Grupo de mal pronóstico (supervivencia del 13 %); además nos permite establecer que pacientes se beneficiaran de recibir un tratamiento sistémico de manera adyuvante [6,[9][10][11][12][13].…”

Section: Introductionunclassified

Índice de Nottingham en cáncer de mama como factor pronóstico y de supervivencia en el Instituto De Cancerología y Hospital Dr. Bernardo Del Valle S. Guatemala

Palacios¹,

Molina²,

Garcia³

2023

Rev Med HJCA

View full text Add to dashboard Cite

BACKGROUND: Breast cancer is the most frequent type of cancer in women. The Nottingham Prognostic Index allows the use of a clinicopathological score, resulting in 3 prognostic groups. The aim of the present study was to determine the survival time and disease-free period and its association with the results of the application of the Nottingham Prognostic Index in patients with early stage breast cancer treated at Instituto De Cancerología y Hospital Dr. Bernardo Del Valle S, Guatemala. METHODS: An observational, descriptive, retrospective study was performed, which included 268 patients who underwent surgery after confirmed diagnosis of breast cancer, stages Ia, Ib, IIa or IIb according to TNM classification, between 2011 and 2014, at Instituto De Cancerología y Hospital Dr. Bernardo Del Valle S, of Guatemala. The study variables were: age, clinical stage, Nottingham index, molecular subtypes, survival and disease-free period, with a minimum follow-up of 5 years, until the last registered control. Chi-square calculation was used to look for correlation between the studied variables, statistical significance was considered with a p ≤ 0.05. RESULTS: The mean age of the patients was 56 years. The most common clinical stage was IIa (50%), among these patients 63% had a moderate prognosis (p ≤0.0001). The most frequent molecular subtype was luminal A (49%), of the patients with this subtype the majority (53% n=70) had a moderate prognosis (p=0.008). Among patients with a poor prognosis according to the Nottingham index, the majority (52.7%) had a disease-free period between 0 and 3 years and only 11% had a disease-free period of 7 or more years (p=0.043). Among those with a poor prognosis, the majority (47%) had a survival time between 0 and 3 years and 40.27% between 4 and 6 years (p=0.027). CONCLUSION: The results of the application of the Nottingham Prognostic Index have statistically significant association with clinical stage (p≤0.0001),molecularsubtype (p=0.008), disease-free period (p=0.043) and survival time (p=0.027); therefore it is a good predictor of survival time and disease-free period for breast cancer, and also allows us to correlate the different molecular subtypes and their prognosis.

show abstract

Section: Introductionunclassified